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Airw ay rem odelling with subepithelial fibrosis, which abolishes the physiological functions of the 
bronchial w all, is a m ajor issue in bronchial asthm a. Human bronchial fibroblasts (H BFs) derived from  
patients diagnosed with asthm a d isplay in vitro predestination tow ards TG F-ß 1-induced fibroblast-to- 
m yofibroblast transition (FM T), a key event in subepithelial fibrosis. A s com m only used anti-asthm atic  
drugs do not reverse the structural changes of the airw ays, and the m olecular m echanism  of enhanced  
asthm a-related TG F-ß 1-induced FM T is poorly understood, we investigated the balance between the 
profibrotic TGF-ß/Sm ad2/3 and the antifibrotic TGF-ß/Smad1/5/9 signalling pathways and its role in 
the m yofibroblast form ation of H B F populations derived from asthm atic and non-asthm atic donors. 
Our findings showed for the first tim e that TGF-ß-induced activation of the profibrotic Smad2/3  
signalling pathw ay was enhanced, but the activation of the antifibrotic Smad1/5/(8)9 pathw ay by  
TG F-ß 1 was significantly  dim inished in fibroblasts from  asthm atic donors com pared to those from their 
healthy counterparts. The im pairm ent of the antifibrotic TGF-ß/Smad1/5/(8)9 pathw ay in HBFs derived 
from asthm atic donors was correlated with enhanced FMT. Furtherm ore, we showed that Sm ad1  
silencing in H B Fs from non-asthm atic donors increased the FM T potential in these cells. Additionally, 
we dem onstrated that activation of antifibrotic Sm ad signalling via BM P7 or isoliquiritigenin [a small- 
molecule activator of the TGF-ß/Smad1/5/(8)9 pathway] adm inistration prevents FM T in HBFs from  
asthm atic donors through dow nregulation of profibrotic genes, e .g ., a -SM A  and fibronectin. Our data  
suggest that influencing the balance between the antifibrotic and profibrotic TGF-ß/Sm ad signalling  
pathways using BM P7-m im etic com pounds presents an unprecedented opportunity to inhibit 
subepithelial fibrosis during airw ay rem odelling in asthm a.
The airway tracts o f patients diagnosed w ith asthm a are characterized by chronic inflam mation along with 
remodelling of the bronchial wall1, 2. This phenom enon is a complex process involving damage to the epithelial 
layer, hypertrophy and hyperplasia o f the sm ooth muscles, enhanced vasculature and the key phenom enon 
subepithelial fibrosis3. The progression of the latter is linked with the expansion of myofibroblasts characterized 
by the high contractile apparatus and secretory hyperactivity of bronchial wall cells for i.e. the overproduction
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of extracellular matrix proteins4, 5. Although, in last years, it was shown the multiple origin of myofibroblasts6, 7, 
recent lineage tracing studies confirm that the main sources of myofibroblasts in bronchial wall are resident 
mesenchymal cells such as fibroblasts and pericytes8-11. In 2009, we were the first to show that the local resident 
bronchial fibroblasts isolated from biopsies derived from asthmatic patients had a substantially higher potential 
for transforming growth factor ß (TGF-ß)-induced fibroblast to myofibroblast transition (FMT) than those from 
their non-asthmatic counterparts12. These cells displayed some inherent features that facilitate their differentia­
tion into myofibroblasts4, 13, 14.
In our previous studies, we showed that the architecture of the actin cytoskeleton, which was associated with 
N -cadherin function14, 15, Cx43 signalling activity16 and the functional status of TGF-ß1 and connective tissue 
growth factor (CTGF)17, 18 as the main stimulators of FMT through the Smad2/3 signalling pathway, participated 
in the efficient myofibroblast transition increase in fibroblasts from asthmatic patients12, 16. However, to date, 
the reason why fibroblasts from asthmatic patients react more strongly to TGF-ß1 and, as a result, show higher 
transformation to myofibroblasts than those of their non-asthmatic counterparts is unclear.
The importance of TGF-ß1 signalling in asthma pathogenesis and its duration has been illustrated by genome- 
wide association studies19, 20 and many physiological and functional studies21, 22. TGF-ß1, which is mainly secreted 
by bronchial epithelial cells and eosinophils, is overproduced in bronchoalveolar lavage fluid (BALF)23 and in 
many lung submucosal cells from patients w ith asthma. Its profibrogenic activity in asthm a is shown by the 
intensification of the im m une response and bronchial rem odelling in different layers o f the bronchial wall, 
including subepithelial fibrosis22.
Cells exposed to TGF-ß1 show activation of type II serine-threonine kinase TGF-ß receptor (TGF-ß-RII), 
which induces phosphorylation of activin receptor-like kinases (ALKs)24-27. ALK5 (also known as TGF-ßRI) 
is a typical ALK activated after TGF-ß1 treatm ent and transm its phosphorylation on regulatory Smad proteins 
(R-Smads) through the Smad2/3 pathway after activation. Although TGF-ß1 is believed to induce Smad2/3 
phosphorylation, some studies have shown that it can also induce Smad1/5/(8)9 phosphorylation, which is 
mainly dependent on ALK1 or ALK2 activity26. Phospho-R-Smads (p-Smad2/3 or p-Smad1/5/9) oligomerize with 
common Smads (Co-Smad; Smad4) and then translocate into the cell nucleus, where they bind gene promoters/ 
enhancers and activate or repress the transcription of target genes28. Inhibitory Smad proteins (I-Smads; Smad 6 
and 7) and Smad ubiquitin regulatory factors (Smurfs: Smurf 1, Sm urf 2 and Arkadia) play a significant role in 
the regulation of signal transduction through TGF-ß/Smad-signalling pathway. Smad7 prevents the activation 
of TGF-ß1 signalling by competitive inhibition of the interaction of R-Smads with TGF-ßRI. Smurf 1 and Smurf 
2 (E3 ubiquitin ligases) play a crucial role in the recognition and ubiquitin-dependent degradation of TGF-ß 
receptors and regulate the basal level of both R Smads (Smad 2, Smad 3 and Smad 1), and I-Smads (Smad 7) 
by targeting them  for degradation28. It was shown that in fibroblasts, Sm urf 2 preferentially targets Smad1 for 
ubiquitination and proteasome-mediated degradation.This protein has a much weaker effect on Smad2 levels, 
but does not affect Smad3 levels29.
Smad2/3 signalling is im portant for extracellular TGF-ß1 stimuli. Smad2/3 pathway activation was reported 
to induce a profibrotic response30-33, whereas Smad1/5/9 activation plays an antifibrotic role in different tissues34, 
35. The Smad1/5/9-regulated pathway is activated mainly by bone morphogenic protein receptors (R-BMPs)24. 
Although our recent reports indicated the involvement of TGF-ß/Smad2/3 signalling in FMT efficiency, whether 
the enhanced TGF-ß1-induced FMT potential in hum an bronchial fibroblast (HBF) populations derived from 
asthmatic donors compared to that of non-asthmatic donors may be the result of differential regulation of Smad 
signalling is still unclear16, 36-38. Thus, elucidation of the cellular/molecular mechanisms by which TGF-ß1 favours 
myofibroblast accumulation during subepithelial fibrosis in asthma remodelling progression remains the aim 
of many research groups. However, a comparison of the activity of the profibrotic Smad2/3 pathway and the 
antifibrotic Smad1/5/9 pathway has never been conducted. To further elucidate the molecular mechanisms of 
FMT based on TGF-ß/Smad signalling in asthma, we used an in vitro model of cultured HBFs isolated from 
ex vivo bronchial biopsies of patients with diagnosed asthma (AS) and donors in whom asthma was excluded 
during clinical diagnosis (NA).
The aim of the present study was to evaluate w hether enhanced asthma-related TGF-ß1 FMT is the result 
of the differential activation of the profibrotic TGF-ß/Smad2/3 and antifibrotic TGF-ß/Smad1/5/9 signalling 
pathways in HBFs.
Results
Enhanced FM T efficiency in H BFs from asthm atic donors is due to the increased activation of 
the profibrotic Smad2/3 pathway. As mentioned above, TGF-ß1-induced FMT was intensified in vitro 
in HBFs from asthmatic patients12, 15, 16. Immunofluorescence analyses of a-sm ooth muscle actin (a-SMA), the 
main marker of myofibroblasts, showed that FMT also occurs much more rapidly in fibroblasts from patients 
with diagnosed asthma than those from non-asthmatic donors after exposure to TGF-ß1 (Fig. 1A,B). These data 
were also confirmed by RT-qPCR and ELISA analyses. The results revealed that HBFs from asthmatic donors 
displayed significantly higher gene expression of a-SMA and extra domain A of fibronectin (EDA-fibronectin), 
especially after TGF-ß1 stimulation, compared with those from their non-asthmatic counterparts (Fig. 1C-E). 
Moreover, the gene expression analyses of the profibrotic factor TGF-ß1 showed that it was correlated with FMT 
efficiency in the HBF populations of both groups (Fig. 1F comp. Fig. 1E and Fig. S1A).
The canonical TGF-ß1/Smad2/3 signalling pathway is crucial for FMT21, 22. Since we previously observed 
enhanced TGF-ß1-induced FMT in HBFs from asthmatic donors, we further focused on analysis of Smad2 and 
Smad3 expression (at the mRNA and protein levels) between HBFs derived from asthmatic and non-asthmatic 
donors. RT-qPCR analyses confirmed that there were no significant differences in Smad2 and Smad3 mRNA 
levels between HBFs from asthmatic and non-asthmatic donors in control conditions and after 24 h of stimulation
Figure 1. HBFs derived from patients with asthma transdifferentiate into myofibroblasts efficiently and faster 
than those of their healthy counterparts. HBFs (AS = 10; NA = 6) were cultured in serum-free conditions in the 
absence or presence of TGF-ß1 (5 ng/mL) for 0-7  days. (A) t t e n ,  the cells were fixed with 3.7% formaldehyde, 
permeabilized, and immunostained for a-SMA (green) and counterstained for DNA (blue), as shown on 
representative images. Scale bar = 25 |tm. (B) t t e  fraction of cells with prom inent a-SMA-positive stress fibres in 
HBF populations was determined using fluorescence microscopy, each in three independent experiments. (C,D) 
Main markers of myofibroblast formation: a-SMA and EDA-fibronectin levels were assessed using in-cell-ELISA 
tests, and the results are presented as the mean value of absorbance (450 nm) reflecting the protein content. Data 
represent the mean ± SeM carried out on HBFs (AS = 10; NA = 6), each in triplicate. (E,F) HBFs (AS = 7; NA = 7) 
were cultured in serum-free conditions in the absence or presence of TGF-ß1 for 24 h. RT-qPCR analyses of 
alpha smooth muscle actin (ACTA2) and TGF-ß1 expression were performed. Statistical significances of all 
experiments were tested using the non-parametric M ann-W hitney test; *p < 0.05, **p < 0.01.
with TGF-ß1 (Fig. 2A). Moreover, Smad2 protein content detected by immunoblots was increased in unstim u­
lated HBFs from asthmatic donors compared to non-asthmatic donors, but TGF-ß1 notably decreased Smad2 
and Smad3 levels in the HBF populations from both studied groups (Fig. 2B). Interestingly, the TGF-ß1-induced 
phosphorylation of Smad2 and Smad3 was significantly stronger in HBFs from asthmatic donors (Fig. 2C,D) 
than those from non-asthm atic donors. Differences in Smad3 phosphorylation were observed after just 5 min 
and were more pronounced than those of Smad2 phosphorylation, which were significant after 15 min of TGF-ß1 
stimulation (Fig. 2C,D). Smad2/3 pathway activation resulted in increased nuclear localization of p-Smad2/3. 
t t e  nuclear translocation o f activated Smad complexes, verified by immunofluorescence, was the strongest 
after 60 min of TGF-ß1 stimulation and further enhanced after 120 min between the studied groups (Fig. 2E,F). 
Moreover, the mean nuclear fluorescence intensity of p-Smad3 was significantly different between AS and NA 
HBFs under control conditions (Fig. 2F).
The antifibrotic Smad1/5/(8)9-dependent pathway is overactivated in H BFs isolated from  
non-asthm atic donors. Because some reports have shown that the Smad1/5/(8)9 pathway plays a cru­
cial antifibrotic role in renal and liver39-41, further analyses were performed to assess TGF-ß1/Smad1/5/9 path­
way activity in the HBF populations from asthmatic and non-asthmatic donors. RT-qPCR studies showed that 
the Smad1 and Smad5 levels were fivefold and tenfold higher, respectively, in HBFs derived from AS donors 
(Fig. 3A) than those from non-asthmatic donors. Interestingly, TGF-ß1 stimulation strongly suppressed Smad1

< Figure 2. The TGF-ßj/Smad2/3 pathway is intensified in HBFs derived from patients with asthma compared to 
their healthy counterparts. Cells (AS = 7, NA = 7) were cultured in serum-free medium with or without TGF-ßj 
(5 ng/mL) for 24 h (A), 48 h (B), 1-60 min (C,D) or 0-240 min (E,F). (A) Smad expression was analysed at 
the mRNA level using RT-qPCR. (B-D) Smad2, Smad3, and their phosphorylated forms were detected using 
Western blots. Representative membranes are shown. Densitometric quantification of Smad proteins in relation 
to ß-actin and p-Smad2 or 3 in relation to appropriate Smads (as control proteins) are presented on the graphs 
as values of relative optical densities (ROD) (n = 6). (E- F) HBFs were fixed, permeabilized, and immunostained 
for p-Smad2 or p-Smad3. Representative photos were selected. Scale bar = 25 pm. The percentage of cells with 
p-Smad + nuclei was determined using fluorescence microscopy. Alternatively, p-Smad levels in HBF nuclei were 
quantified with the fluorometric approach using ImageJ, and the results are presented as the mean fluorescence 
intensity in relation to the nuclei area. Data on photos (yellow) represent the mean ± SEM of AS = 5, NA = 5; each 
in min. 100 cells. Statistical significance (C- F) * between HBFs AS TGF vs HBFs NA TGF; (F) # HBFs AS CTRL 
vs HBFs NA CTRL. Statistical significance was tested using the non-parametric M ann-W hitney test; * p  < 0.05,
**p < 0.01, *** p  < 0.001.
expression, which was similar in the fibroblasts derived from both study groups. The effect of TGF-ßj on Smad5 
expression was undetectable (Fig. 3A). Parallel im munoblot analyses revealed differences between the Smads at 
the protein level in the HBFs from both study groups (approximately threefold increases in both the Smad1 and 
Smad5 levels in unstimulated HBFs from asthmatic donors) (Fig. 3B). However, TGF-ß1 stimulation strongly 
decreased Smad1 but not Smad5 contents in HBFs from patients with asthma. The level of the E3 ubiquitin- 
protein ligase Smurf2 was also increased in AS HBFs. A comparison of the Smad1/5/9 pathway activity between 
HBFs derived from asthmatic and the non-asthmatic donors was performed by immunoblots and immunofluo­
rescence analysis. A representative immunoblot membrane showed a time-dependent increase in the phospho­
rylation of Smad1/5/9 after TGF-ß1 treatment, resulting in faster and stronger (three times) phosphorylation of 
Smad1/5/9 in the HBFs from non-asthmatic donors than those from asthmatic donors (Fig. 3C). Moreover, the 
nuclear localization of phosphorylated Smad1/5/9 complexes, shown on representative images and measured 
fluorometrically, was also enhanced in HBFs from non-asthmatic donors after TGF-ß1 treatm ent (Fig. 3D). Since 
it is well documented that phosphorylated R-Smads translocate into nucleus in complexes with Co-Smads we 
compared the expression of Smad 4 at the mRNA and protein levels in the HBFs from both study groups. Our 
results of RT-qPCR analyses showed significantly higher Smad 4 expression in HBF populations derived from 
asthmatics (Fig. S1D). Interestingly, immunoblot analyses revealed no differences between Smad 4 at the protein 
level in the HBF populations from AS and NA donors (Fig. S1E).
Silencing of S m a d l in the H BFs derived from non-asthm atic donors leads to Smad2/3 path­
way stim ulation and FMT activation. To illustrate the impact of the opposing Smad-dependent path­
ways on FMT, we silenced the Smad1 gene in HBFs. The immunofluorescence staining of p-Smad2/3 proteins 
after 1 h  of TGF-ß1 administration showed that Smad1 silencing had no impact on Smad2/3 pathway activation 
in the HBFs from asthmatic donors, but it caused a twofold increase in p-Smad2/3 activity (enhanced nuclear 
translocation of p-Smad2/3 complexes) in the HBFs from non-asthmatic donors (Fig. 4A). This observation was 
confirmed by fluorometric analysis (Fig. 4B,C). This change resulted in the intensification of the FMT process 
(Fig. 4A). The immunofluorescence analyses showed that stress fibres consisting of a-SMA were increased after 
Smad1 silencing in the HBF populations from non-asthmatic donors (Fig. 4A, inserts with plots).
Activation of Smad1/5/(8)9 signalling prevents FMT in H BFs from asthm atics. We used BMP7, 
which is described as a main activator of the Smad1/5/(8)9 pathway42-44, to assess the impact of Smad1/5/9 acti­
vation on the FMT process in HBF populations. Immunofluorescence analyses showed that BMP7 stimulates 
the myofibroblast transition of HBFs from asthmatic donors, but this process was much weak than after TGF-ß1 
administration (Fig. 5A,B,C). These microscopic observations were confirmed by fluorometric analyses, which 
revealed shorter, thinner and less enriched a-SMA actin stress fibres in BMP7-treated HBFs compared to TGF- 
ß1-stimulated HBFs (Fig. 5A,B). The combination of BMP7 and TGF-ß1 decreased the FMT potential (measured 
as the num ber of myofibroblasts) in the HBFs derived from asthmatic patients but not in those from their non­
asthmatic counterparts (Fig. 5C). However, a-SMA levels were not reduced after TGF-ß1 and BMP7 treatm ent 
in the HBFs derived from asthmatic donors (Fig. 5D,E). These results suggested that BMP exerts an inhibitory 
effect on the TGF-ß1-induced FMT by affecting the actin cytoskeleton architecture.
Further analyses were performed to estimate the effect of isoliquiritigenin (ISL), described as a small molecule 
activator of BMP signalling45, on the TGF-ß1-induced FMT in the HBF populations derived from asthmatic 
patients. ISL (used at a concentration that did not affect cell viability and proliferation, Fig. S1F,G) attenuated the 
TGF-ß1-induced phenotypic differentiation of HBFs, as shown by a reduction in the fraction of myofibroblasts 
in the HBF populations (Fig. 6A,B). Concomitantly, ISL decreased the a-SMA and fibronectin levels in TGF- 
ß1-treated HBFs (Fig. 6C,D). Moreover, im munoblot analyses confirmed that ISL-induced FMT attenuation is 
dependent on Smad1/5/9 pathway overactivation (Fig. 6E).
Discussion
A major problem of bronchial remodelling in asthma is progressive subepithelial fibrosis, which causes irrevers­
ible changes in the bronchial wall1, 2 5 46. The strong accumulation of contractible (overexpression of a-SMA) 
myofibroblasts secreting excessive amounts of extracellular matrix proteins (fibronectin, collagens, proteoglycans) 
abolishes the physiological functions of the bronchi. FMT, a crucial event during subepithelial fibrosis observed
Figure 3. t t e  TGF-ß1/Smad1/5/9 pathway is intensified in HBFs derived from patients without asthma 
compared to asthmatic patients. (A) Cells were cultured in serum-free medium supplemented with TGF-ß1 
(5 ng/mL) for 24 h. t t e n ,  the mRNA was isolated, and transcripts were analysed using RT-qPCR. (B) Smad1, 
Smad5, and Smurf2 were detected using Western blots. Representative membranes are shown. Densitometric 
quantification is presented on the graphs as values of the relative optical densities (ROD) (n = 6) of the bands 
in relation to that of ß-actin (control protein). (C) Phosphorylated forms of Smad1/5/9 (p-Smad1/5/9) were 
detected using Western blots. Representative membranes are shown. Densitometric quantification is presented 
on the graph as values of the relative optical densities (ROD) (n = 4) of p-Smads in relation to Smad1 (as the 
control protein) (D) HBFs cultured in serum-free medium were fixed, permeabilized, and immunostained for 
p-Smad1/5/9, and the percentage of cells with p-Smad1/5/9-positive nuclei was determined using fluorescence 
microscopy. Representative photos were selected. Scale bar = 25 pm. t t e  mean fluorescence intensity in relation 
to the nuclei area (AS = 3, NA = 3 each in 200 cells) was measured using ImageJ. Statistical significance was tested 
using the non-parametric M ann-W hitney test; *p < 0.05, ***p < 0.001 or the T-test; #p < 0.05.
in asthma, depends on the combined action of inflammatory mechanisms and inherent features of airway wall 
fibroblasts facilitating their phenotypic transitions in response to hum oural factors4. t t e  induction of the FMT 
in HBF populations in vitro by the addition of exogenous TGF-ß1 mimics the in vivo asthmatic process trig­
gered by local secretion of TGF-ß1 (the most im portant pro-fibrotic cytokine22) within the inflammatory milieu. 
tte re fo re , the experim ental model, based on the prim ary HBFs expanded directly from bronchial biopsies 
of different patients w ith or w ithout diagnosed asthma, is suitable for the analyses of the FMT background 
in asthma, as well as for pharm acokinetic studies. O ur model may have some limitations related to potential 
confounders such as a younger age and steroid use in the asthmatic patients in comparison to control subjects. 
However, due to propagation of HBFs for several passages in a culture, in our opinion, this model gives a pos­
sibility to describe the differences between cells isolated from individual patients, which are related to genetic 
and epigenetic background rather than to a chronic inflammation or to consequences o f drugs taken by the 
patients. W hen it comes to the age differences between the both groups of patients used in our study they result
Figure 4. The Smad2/3 pathway is overactivated in HBFs derived from patients without asthma after Smad1 
silencing. (A) HBFs cultured in serum-free medium were transfected with siRNA-Smad1 or control-siRNA, 
treated with TGF-ß1 (5 ng/ml) for 1 h  (photos) and 5 days (inserts), fixed, permeabilized, and immunostained 
for p-Smad2/3 (red) and a-SMA (green), as shown on representative images and inserts. The fluorescence 
intensity of a-SMA-enriched fibres is presented on the plot profiles (under the photos). (B,C) Fluorescence 
intensity of p-Smad2/3-positive nuclei was determined using fluorescence microscopy at the same excitation 
and analysed by ImageJ. Representative photos were selected. Scale bar = 100 pm. Data represent the 
mean ± SEM of 100 cells (AS = 3, NA = 3); each in duplicate. Statistical significance was tested using one-way 
ANOVA with the Bonferroni multiple comparison post hoc test; ###p < 0.001.
from difficulties in recruiting individuals to the control group, from which we could have obtained consent and 
take samples from the lower respiratory tract by bronchoscopy. Although aging is recognized as a major risk 
factor for fibrotic diseases47 and FMT has been shown in in vitro studies to strongly increase with age48, in our 
studies a younger age of the asthmatic patients, in comparison to the control subjects, did not affect the enhanced 
TGF-ß1-induced asthma-related FMT.
The FMT process is inextricably linked to profibrotic signalling from TGF-ß receptors through a TGF-ß/ 
Smad2/3-dependent pathway. Our previous12, 15, 16 and current observations indicate that FMT is more efficient in 
the fibroblasts from asthmatic donors after TGF-ß1 treatm ent than those from their non-asthmatic counterparts. 
Based on many reports describing the antifibrotic role of the Smad1/5/9 pathway in various diseases35, 49, 50, we 
compared profibrotic Smad2/3 and antifibrotic Smad1/5/9 signalling activity between the HBFs from asthmatic 
and non-asthm atic donors. The association of TGF-ß/Smad2 signalling activity with airway rem odelling in 
asthma has been poorly investigated51. We are the first to demonstrate that the intensification of the fibrogenic 
potential of AS HBFs was associated with increased activity of the profibrotic TGF-ß/Smad2/3-dependent path­
way in these cells. Both the level of phosphorylation of the Smad2 and Smad3 proteins and the nuclear transloca­
tion of their complexes were increased in AS HBFs, while NA HBFs showed much weaker activation of this path­
way in vitro (Fig. 7). Such an increase in the phosphorylation of Smad2 and Smad3 was previously observed in 
mouse lung tissues after prolonged allergen challenge (ovalbumin)52, 53 and in hum ans in acute allergen-induced 
remodelling during asthma54, 55. The observed intensification of the TGF-ß/Smad2/3 pathway in AS HBFs may 
be related to the enhanced expression of TGF-ß receptors, especially ALK5 (Fig. S1B)56, because the TGF-ßRII 
level is the same in NA and AS HBFs36, 56. Dysregulation of the Smad2/3 pathway through blocking of TGF-ß 
receptors (pharmacologically and using specific antibodies) was used to decrease the FMT potential and fibrosis, 
but this treatm ent may disturb the balance of norm al processes in other cells of the organism37, 49, 57. Therefore, 
substances that act downstream in the TGF-ß/Smad2/3 pathway, such as inhibitors of Smad2/3 phosphorylation 
or nuclear translocation inhibitors (SIS3, statins, fenofibrate, etc.), are continually being assessed16, 37, 38.
However, some studies have shown that TGF-ß can induce not only Smad2/3 phosphorylation via TGF- 
ßRII/ALK5 binding but also Smad1/5 phosphorylation dependent on different receptor complex activities (e.g., 
ALK1/2/3/6) in a cell type-specific m anner58, 59. Taken together, these observations suggest that further studies 
are needed to determine whether TGF-ß1 can differentially bind to heteromeric complexes comprised of varied 
mammalian TGF-ß family type I and type II receptors and can thus activate TGF-ß/Smad pathways in diverse 
mechanisms in HBFs from asthmatic and non-asthm atic donors.
Smad1/5/9 pathway activation has been shown previously to have potent antifibrotic effects in liver fibrosis41, 
renal fibrosis39, 60, pulm onary fibrosis61-63 and myocardial fibrosis64 in animals and humans. We reported that 
TGF-ß/Smad1/5/9 pathway activity is increased in HBFs from non-asthmatic donors compared to HBFs obtained 
from patients with asthma. A co-Smad4 is necessary for the nuclear translocation of Smad complexes, such as 
p-Smad2/3/4 and p-Smad1/5/428. The observed impairment of Smad1/5 phosphorylation in TGF-ß-treated HBFs 
from asthmatic donors along with a lack of differences in Smad4 levels between NA and AS HBFs (Fig. S1D,E)
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< Figure 5. Smad2/3 versus Smad1/5/9 activation balance plays a pivotal role in fibroblast to myofibroblast 
transition of HBFs. (A,B) HBFs were cultured in serum-free medium without (Ctrl) or with TGF-ß1 (5 ng/ 
ml) in the absence or presence of BMP7 (100 ng/ml) for 7 days. t t e n ,  the cells were fixed, permeabilized, 
and immunostained for a-SMA (green) and counterstained for F-actin (red) and DNA (blue), as shown on 
representative images. t t e  intensity of actin fibre fluorescence in the sections is presented on plot profiles and 
quantified in graphs (under the photos). Scale bar = 200 pm. (C,E) t t e  fraction of cells with prominent a-SMA- 
positive stress fibres in HBF populations was determined using fluorescence microscopy in three independent 
experiments. (D,F) Analyses of a-SMA content were carried out using an in-cell ELISA test, and the results 
are presented as the mean value of absorbance (450 nm) reflecting the protein content. Data represent the 
mean ± SEM carried out on HBFs (AS = 10; NA = 6), each in triplicate. (G) a-SMA was detected using Western 
blots. Representative membranes are shown. Glyceraldehyde 3 phosphate dehydrogenase (GAPDH) was used 
as a loading control. (H) Densitometric quantification of membranes is presented on the graph as values of the 
relative optical densities (ROD) (n = 2) of a-SMA in relation to GAPDH (as control protein) (A,C,D) HBFs from 
asthmatics, (B,E,F) HBFs from non-asthmatics. Statistical significance was tested using were determined using 
Statistical significance was tested using one-way ANOVA with the Bonferroni multiple comparison post hoc 
test; ns -  non statistically significant, *p < 0.05, **p < 0.01, ***p < 0.001.
indicated overactivation of the profibrotic Smad2/3 pathway in AS HBFs. O ur data are consistent with the obser­
vations that the basal expression of R-BMPs and Smad1/5 pathway activation are reduced in bronchial cells from 
patients with m ild asthma65. t t e  imbalance between the Smad1/5/9 and Smad2/3 ratio in AS HBFs can inten­
sify the production of TGF-ß1, fibronectin, a-SMA and collagens, leading to enhanced FMT and subepithelial 
fibrosis. We showed that TGF-ß1 stimulation strongly decreased the Smad1 level in AS HBFs. t t i s  change may 
be caused by the increased Smurf2 level, which can degrade Smad129, 66, resulting in additional im pairm ent of 
the Smad1/5/9 pathway and inhibition of its protective antifibrotic role. Moreover, the silencing of Smad1 in NA 
HBFs by siRNA mediated the signal transfer from the antifibrotic TGF-ß/Smad1/5/9 to the profibrotic TGF-ß/ 
Smad2/3 pathway and stimulated FMT in vitro.
BMP7 is known as a cytokine that can antagonize the TGF-ß1-dependent fibrogenic activity of mouse pu l­
m onary myofibroblastic cells62. t t i s  cytokine is also a main stimulator of the Smad1/5/9 pathway43. We showed 
that canonical BMP7 stimulation of the Smad1/5/9 pathway dysregulates a-SMA synthesis in both untreated and 
TGF-ß1-treated HBFs from healthy donors. Similar results have been obtained by Pegorier et al. and Midgley 
et al. on norm al hum an lung fibroblasts cultured in vitro in combination with TGF-ß167, 68. In our model, BMP7 
stimulation of the Smad1/5/9 pathway reduced the efficiency of TGF-ß1-induced FMT in AS HBFs by decreas­
ing the percentage of myofibroblasts in HBF populations. Surprisingly, cotreatm ent of AS HBFs with TGF-ß1 
and BMP7 did not decrease a-SMA production; however, we observed disruption of a-SMA incorporation into 
actin stress fibres16, 38 and a consequent reduction in the formation of myofibroblasts. It is well documented that 
myofibroblast formation in a variety of tissues, including hum an bronchi, demands not only hum oral factors 
(e.g. TGF-ß) but also mechanical stimuli (e.g. appropriate cell stiffness and/or the interaction of cells with ECM 
proteins)4. Previously we have shown that HBFs from asthmatics form an increased num ber of thick stress fibres 
accompanied by enlarged focal adhesions which correlate with high elastic modulus of asthmatic HBFs and 
their increased efficiency to the TGF-ß-induced FM T14. Taken together, our results demonstrate that BMP-7 
(without affecting the level of a-SMA) induces changes in the actin cytoskeleton architecture in HBFs causing 
decreased cell stiffness, which correlate with the reduced FMT in BMP-7-treated HBF populations. t t e s e  find­
ings may be related to the previously shown im pairm ent of the TGF-ß/Smad1/5/9 pathway in AS HBFs. t t i s  
im pairment may be a reason for the dysregulation of the Smad1/5/9 pathway by upstream stimulation by BMP7 
and TGF-ß1 (Fig. 7). Additionally, a recent report showed that in a mouse model of asthma, the balance between 
TGF-ß1 and BMP7 could be used to predict the intensity of lung fibrosis61. Moreover, the levels of the TGF-ß1 
and TGF-ß receptors, unlike the level of BMP7 and its receptors, were higher in the bronchi of asthmatics than 
the non-asthm atic controls61, 65. t t e  results from multiple fibrotic disease models dem onstrated that BMP7 
expression is downregulated during tissue fibrosis and that treatm ent with BMP7 prevented fibrotic changes36, 
46, 61. Despite the promising reports from various animal studies, exogenous BMP7 has not yet been approved for 
use in hum an fibrotic diseases or even in preclinical studies, probably because BMP7 is costly and its clinical use 
is lim ited due to the supraphysiological doses required for therapeutic efficacy, which cause severe side effects. 
BMP7 is also likely rapidly cleared from the blood49. Given the above results, we decided to search for small 
molecule activators of BMP signalling. Based on the results of Vrijens et al., we chose ISL as a small activator 
of Smad1/5/9 signalling45. We demonstrated for the first time that in our in vitro model, ISL at non-cytotoxic 
and non-cytostatic concentrations notably attenuated the TGF-ß1-induced phenotypic transition of AS HBFs 
into myofibroblasts through Smad1/5/9 pathway stimulation (Fig. 7). As we noted previously, the experimental 
model used in this study mimics the basic properties of HBFs during asthma and the chronic inflammation 
crucial for this disease. t t u s ,  our results indicated that this agent may attenuate in vivo airway wall remodelling 
via a TGF-ß desensitizing effect on HBFs. Earlier studies showed that ISL decreased the levels of IL-4 and IL-5 
in allergic asthma, significantly improving the function of the lungs69, 70, and it may relax guinea-pig trachea 
through multiple intracellular actions71. ISL supplementation reduced high fat diet (HFD)-induced adipose tissue 
fibrosis and the expression of fibrosis-related genes in mice72. A recent report showed that ISL can also attenuate 
monocrotaline-induced pulmonary hypertension via its anti-inflammatory and antiproliferative actions in rats73. 
t t u s ,  our and other results suggest that ISL is a strong candidate for antifibrotic therapy in asthma.
Taken together, our data shed light on FMT signalling in bronchial asthma when the disordered balance 
between the Smad2/3 and Smad1/5/9 pathways is considered. Based on our results, we strongly suggest that 
enhanced asthma-related FMT (the key event of subepithelial fibrosis in the bronchial wall of asthmatic patients)
Figure 6. Isoliquiritigenin (ISL) attenuates the TGF-ß1-induced phenotypic transition of HBFs into 
myofibroblasts through Smad1/5/9 pathway stimulation. (A) HBFs derived from asthmatic donors were 
cultured in serum-free medium supplemented with TGF-ß1 (5 ng/mL) or not (Ctrl) in the absence or 
presence of ISL (25 pM) for four days. ’Hien, the cells were fixed with 3.7% formaldehyde, permeabilized, and 
immunostained for a-SMA (green) and DNA (blue), as shown on representative images. Scale bar = 25 pm.
(B) t t e  fraction of cells with prom inent a-SMA+ stress fibres (myofibroblasts) in HBF populations (n = 6) 
was determined using fluorescence microscopy in three independent experiments. (C) a-SMA content was 
defined using in-cell ELISA, and the results are presented as the mean value of absorbance (450 nm) reflecting 
the protein content. Data represent the mean ± SEM carried out on HBFs AS (n = 6), each in duplicate. (D) 
Analyses of a-SMA and fibronectin content were carried out in total cell lysates from HBFs cultured as in (A) 
using immunoblotting. Glyceraldehyde 3 phosphate dehydrogenase (GAPDH) was used as a loading control. 
t t e  effect of ISL on the a-SMA levels in the TGF-ß1-treated HBFs is presented as a bar graph and shows 
densitometric quantification of the Western blots. Data are the mean ± SEM (n = 5). (E) t t e  activation of the 
Smad1/5/9 pathway was determined using Western blot analysis of Smad1/5/9 phosphorylation in relation to 
Smad1 and GAPDH as a loading control. Statistical significance was tested using the t-test; *p < 0.05, **p < 0.01, 
**,p  < 0.001.
depends on TGF-ß/Smad1/5/(8)9 pathway impairment (Fig. 7). In connection with the above findings, the usage 
of substances stimulating this antifibrotic pathway (such as ISL) may prove to be an effective way to suppress 
FMT and subepithelial fibrosis in asthma, but the exact molecular mechanism of the phenom enon reported 
here requires further studies.
Materials and methods
Patient characteristics. For the study, 10 patients with asthma severity 3-5 (according to the Global Ini­
tiative for Asthma (GINA) classification) and 7 control subjects were included. All patients were treated in the 
Department of Medicine of the Jagiellonian University Medical College and remained in stable clinical condi­
tions. t t e  control subjects were selected from the group of patients who were referred for bronchoscopy due 
to prolonged cough. t t e s e  patients had previous thorough, extensive diagnostics, during which other diseases 
causing cough were excluded by means of anamnesis and additional tests (imaging, lung function tests, histo- 
pathological examination of bronchial samples, allergic tests, microbiological tests). t t e y  were finally diagnosed 
with post-infectious or idiopathic cough. All participants have never smoked. COPD was excluded by the his­
tory and the correct result of spirometry, including FEV1/FVC ratio after bronchodilator > 0.7. tte refo re , it did 
not affect the results.
Figure 7. Schematic representation of interrelations between profibrotic Smad2/3-dependent and anti-fibrotic 
Smad1/5/(8)9-dependent pathways in HBFs. TGF-ß1-activated profibrotic Smad2/3 pathway is enhanced in 
HBFs derived from asthmatic patients (|AS; red) than in its non-asthmatic (NA) counterparts (both at the level 
of phosphorylation of Smad2/3 proteins and their intranuclear translocation). However, in response to TGF-ß1 
exposition, HBFs NA shows the increased activation of anti-fibrotic Smad1/5/(8)9 pathway (|N A ; green) (both 
at the level of phosphorylation of Smad1/5/(8)9 proteins and their intranuclear translocation). Isoliquiritigenin 
(ISL), is able to increasing the activation of Smad1/5/(8)9-dependent pathway (|AS; green) and concomitant 
attenuation of pro-fibrotic potential in HBFs AS. Dysregulation of balance between profibrotic Smad2/3 and 
anti-fibrotic Smad1/5/(8)9 pathway may leads to the enhanced fibrogenic potential of asthmatic HBFs (|AS; 
red). t —activation of pro-fibrotic pathway (red); t —activation of anti-fibrotic pathway (green); Abbreviations: 
TGF-ß1 transforming growth factor-ß1; BM P7bone morphogenic protein 7; ISL isoliquiritigenin; SBE Smad 
binding elements; HBFs human bronchial fibroblasts; AS  asthmatic; NA  non-asthmatic; P phosphorylation sites; 
ERK1/2 extracellular signal-related kinase 1/2.
Detailed characteristics of asthma patients and control subjects are presented in Table 1.
Although the studied groups of donors differ in the mean age, in our opinion, a younger age of asthma 
patients in comparison to control subjects has no effect on the study outcomes. Age differences are mainly due 
to the fact that it was difficult to recruit theoretically “healthy” subjects for the control group and to collect from 
them  samples from the lower respiratory tract by bronchoscopy. ’tte refo re , we recruited all suitable subjects 
regardless their age.
t t e  study was approved by the Jagiellonian University Ethics Committee (Decision No. 122.6120.16.2016). 
All patients and control subjects gave written informed consent to participate in the study.
All methods were perform ed in accordance with the relevant guidelines and regulations.
Isolation and culture of primary H BFs. Primary HBFs were established from the explants of bronchial 
biopsies obtained from patients during bronchoscopy using a fiberoptic bronchoscope (Olympus). Then, the 
explants were washed with cold phosphate buffered saline (PBS, Corning) and transferred to fibroblast growth 
medium (FGM; Fibroblast Basal Medium containing 2% FBS and supplements from the FGM-2 Bullet Kit; 
Lonza) with collagenase IV (Worthington, USA; 1 mg/ml) at 37 °C. After 5-6 h of incubation with intensive 





Sex (Female/Male) 6/4 4/3
Age (years), mean ± SD 42.8 ± 15.2 56.8 ± 9.5
F E V ^  predicted, mean ± SD 67.3 ± 22.5 97.17 ± 11.1
FEV1/FVC ratio before bronchodilator, mean ± SD 0.65 ± 0.6 0.83 ± 0.7
FEV1/FVC ratio after bronchodilator, mean ± SD 0.75 ± 0.5 0.85 ± 0.4
Asthma duration (years), mean ± SD 17.0 ± 13.8 NA
Treatment with ICS, n (%) 7 (70) NA
ICS (pg/day)3, mean ± SD 642.9 ± 349.3 NA
Treatment with OCS, n (%) 3 (30) NA
OCS (pg/day)b, mean ± SD 8.7 ± 7.0 NA
Table 1. Patient characteristics. ICS, inhaled corticosteroids; OCS, oral corticosteroids; NA, non-applicable. 
“Maintenance dose, fluticasone propionate equivalent. bMaintenance dose, methylprednisolone equivalent.
maximally extended using sterile needles. Primary cultures of HBFs were established in FGM for 3 weeks with 
FGM replacement every 48-72 h. Next, the cells were passaged and, after centrifugation (300xg; 5 min), sus­
pended in complete Dulbecco’s modified Eagle’s medium containing high glucose (DMEM, Sigma-Aldrich, St. 
Louis, MO, USA) supplemented with 10% foetal bovine serum (FBS, GibcoTM, Thermo Fisher Scientific) and 
a penicillin/streptomycin cocktail (P4333; Sigma-Aldrich, St. Louis, MO, USA). Cells were cultured in standard 
conditions (37 °C and 5% CO2) to 80-85% confluence and used for experiments between the 5th and 15th pas­
sages. We used cells from new isolations (fresh cells) and cells that were deposited in the cell bank (frozen cells). 
Cells from similar passages (± 1 passage) as well as fresh cells or frozen cells from both studied groups were 
used for each experiment comparing HBFs AS and NA. The phenotype of established prim ary cultures of HBFs 
was verified by immunofluorescence staining of a-SMA, vimentin and desm in14. All cells expressed vimentin- 
positive staining, whereas desmin expression was not observed. In HBF populations derived from asthmatic 
patients, a-SMA-positive staining was observed in ca. 5% cells. For each experiment, cells were seeded at a den­
sity of 5000 cells/cm2, cultured in complete medium for 24 h, and then cultured in serum-free m edium—DMEM 
containing 0.1% bovine serum albumin (BSA, Sigma-Aldrich, St. Louis, MO, USA) in the absence or presence 
of hum an recombinant TGF-ß1 (5 ng/ml; BD Bioscience; dissolved in a solution of 1 mg/ml BSA/PBS) and/or 
BMP7 (100 ng/m l Sigma-Aldrich, St. Louis, MO, USA) and/or ISL (25 pM; Sigma-Aldrich, St. Louis, MO, USA).
Cytotoxicity and proliferation assays. For the determination of the cytotoxic/cytostatic effect of ISL on 
HBFs we seeded cells at a concentration of 2.5 x 104 cells/cm2 in culture medium into microplates (96 wells, flat 
bottom; VWR). 24 h after seeding, we added different concentrations of ISL (12.5 pM, 25 pM, 50 pM, 75 pM, 
100 pM). After the incubation period (24 h, 72 h and 4 days), we performed the MTT assay (due to manufacturer 
protocol) for determination of cytotoxicity and Crystal Violet assay for determination of cells’ proliferation. The 
absorbance of the samples was measured using a microplate reader (Multiscan FC; Thermo Fisher Scientific). 
The wavelength to measure absorbance of the formazan product was 570 nm  and for crystal violet was 540 nm. 
IC50 was calculated for each time of incubation with ISL.
Gene silencing. Silencing of Smad1 expression in HBFs was conducted in antibiotic-free medium supple­
mented with 10% FBS using Lipofectamine™2000 according to the manufacturer’s protocol as a carrier for small 
interfering RNA (10 pM solution of siRNA-Smad1 duplex; sc-29483; Control siRNA-A; sc-37007; Santa Cruz 
Biotechnology). After 4 h  of incubation, the medium was replaced with serum-free DMEM with 0.1% BSA and 
antibiotics. The transfected HBFs (silencing efficiency about 60%; Fig. S1C) were used for further experiments.
Imm unofluorescence studies. HBFs were cultured for different periods (1 m in-2  h for p-Smads; 7 days 
for a-SMA staining) in serum-free medium in the presence or absence of TGF-ßj and then fixed with 3.7% 
formaldehyde/PBS. The following antibodies were used: anti-Smads/p-Smads from Smad1/5/9 (#12656) and 
Smad2/3 (#12747) Antibody Sampler Kits (Cell Signaling; all: 1:100). Stress fibres containing a-SMA were vis­
ualized using mouse monoclonal IgG against a-SMA (Sigma-Aldrich, St. Louis, MO, USA) with appropriate 
secondary antibodies (goat-anti mouse IgG conjugated with Alexa Fluor 488). Samples were counterstained by 
phalloidin conjugated with Alexa Fluor 546 (Life Technologies, Thermo Fisher Scientific). Some samples were 
counterstained with Hoechst 33258 (1 pg/ml, Sigma-Aldrich, St. Louis, MO, USA). The images were acquired 
using a Leica DMI6000B inverted microscope (Leica Microsystems, Wetzlar, Germany) equipped with LAS-X 
software for image processing. Smad signalling pathway activation is presented as a percentage of cells with 
strong signals of the phosphorylated forms of Smads from the nuclear area. In turn, the effectiveness of FMT was 
determined by the percentage of cells with a-SMA-positive microfilaments.
Quantification of the obtained results was perform ed using plot profiles perpendicular to bundles of stress 
fibres with quantification of the signal for particular spikes or fluorescence intensity of the nuclear areas (for 
Smad activity). Fiji ImageJ 1.51 s was used to measure these signals. Finally, the averaged fluorescence signal of 
the analysed p-Smads (for at least 100 cell nuclei) in relation to the averaged DNA-specific fluorescence intensity
Gene name
Sequence 5 '-3 ’
Forward Reverse
ACTA2 (a-SMA) CTGTTCCAGCCATCCTTCAT CCGTGATCTCCTTCTGCATT
Smad1 ACCTGCTTACCTGCCTCCTG CATAAGCAACCGCCTGAACA
Smad2 CGT CCAT CTTGCCATT CACG CT C A AGCT CAT CTA AT CGTCCT G
Smad3 GCGTGCGGCT CTACTAC AT C GCACATT CGGGT CAACTGGTA
Smad5 CT GGG ATTAC AGG ACTTGACC A AGTT CC A ATTA A A A AGGG AGG A
TGF-ß1 AGGGCTACCATGCCAACTTCT CCGGGTTATGCTGGTTGTACA
GAPDH GAAGGT GAAGGT CGGAGT GAAGATGGTGATGGGATTTC
Table 2. Primers used for quantitative PCR.
from the surface of proper cell nuclei, was compared between the conditions. Cytofluorimetric analyses of 
p-Smad levels were performed using the same excitation/exposure settings16, 38.
Imm unoblots. Preparation of protein supernatant from cultured cells was described previously16, 38. Sam­
ples containing 20 pg of proteins were electrophoresed on a 10% SDS-polyacrylamide gel and transferred to 
PVDF membranes (Bio-Rad) according to a previously described protocol16, 38.
Next, the membranes were incubated overnight at 4 °C with prim ary antibodies against Smad proteins from 
the Smad2/3 Antibody Sampler Kit and the Smad1/5/9 antibody Sampler Kit, mouse monoclonal IgG against 
a-SMA, mouse monoclonal IgG against ß-tubulin, mouse monoclonal IgG against ß-actin, mouse monoclonal 
IgG against vinculin and mouse monoclonal IgM against glyceraldehyde 3 phosphate dehydrogenase (GAPDH) 
(All: Sigma-Aldrich, St. Louis, MO, USA; 1:1000), diluted in 1% BSA/PBS. After three washes with Tris-buffered 
saline with Tween 20 (TBST), the membranes were exposed to horseradish peroxidase-conjugated anti-mouse 
or anti-rabbit IgG (all: 1:3000, Life Technologies). Band detection was perform ed using Luminata Crescendo 
Western HRP Substrate (Merck Millipore), and the chemiluminescence imaging system ChemiDoc XRS + (Bio­
Rad) was used. Band intensities were quantified using Fiji ImageJ 1.51 s freeware.
Cell-based enzym e-linked im munosorbent assay (in-cell-ELISA ). HBFs were grown in 96-well 
plates in serum-free medium alone or in combination with hum an recombinant TGF-ß1 (5 ng/ml) for 7 days. 
An in cell ELISA protocol38 was performed using antibodies against a-SMA (the same as used in the im m uno­
fluorescence analyses and Western blot) or fibronectin (1:2000 in 1% BSA/PBS). ^ e  results are presented as an 
absorbance value (450 nm; Microplate Reader, ^ e r m o  Scientific, Multiskan FC) corresponding to the relative 
amount of protein levels.
Real-time PCR. Isolation of mRNA from HBFs was performed using the GeneMATRIX Universal RNA/ 
miRNA Purification Kit (EURx, Gdańsk, Poland) according to the manufacturer’s protocol. ^ e  concentration 
of isolated mRNA was measured in a NanoDrop spectrophotometer (Implen) at OD260/280 nm. Two thousand 
nanograms of extracted mRNA, the NG dART RT-PCR Kit (EURx) and C1000 Touch d e rm a l  Cycler (Bio-Rad) 
were used for cDNA synthesis. Gene expression was measured with SYBR Green PCR Master Mix (Applied Bio­
systems) and specific prim er sets (described in Table 2; all from Genomed, Warszawa, Poland) using the 7500 
Fast System (Applied Biosystems). Relative amounts of genes were estimated using the quantification threshold 
value recalculated against GAPDH  transcripts by the ACT m ethod [ACT refers to CT(tested gene)-CT(GAPDH)] and are 
presented as a 2-ACt mean value.
Statistical analysis. ^ e  statistical significances were determined using the non-parametric M ann-W hit­
ney test (the comparison between groups HBFs NA and HBFs AS) or the t-test (the comparison in one group 
between two different experimental conditions) due to the small number of groups and a lack of normal distri­
bution of data. For the data with normal distribution of data (num ber of measurements > 50), statistical signifi­
cance was tested using one-way ANOVA with the Bonferroni multiple comparison post hoc test. ^ e  differences 
were considered to be statistically significant at probability levels of *p < 0.05%, **p < 0.01%, ***p < 0.001%. Each 
parameter was calculated as the mean (± SEM).
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